digital cryptocurrencies, Featured

Pimco and Fidelity believe that the economic outlook in the euro zone is weak, and the European Central Bank has cut interest rates by more than market expectations. Investors such as Pimco and Fidelity International believe that the economic outlook in Europe is bleak, which may force policymakers to cut interest rates by more than market expectations. The latest market pricing shows that the European Central Bank is expected to cut its key interest rate to 1.75% next year. The bank cut interest rates for the third time in a row on Thursday, to 3%. However, Fidelity said that the borrowing cost may be further reduced to 1.5%, and Pimco also believed that there was a risk of a larger interest rate cut. Further repricing may aggravate the rise of European bonds, which have outperformed the US and UK bond markets in 2024. A Bloomberg index, which tracks the return of euro bonds, has risen by more than 3% this year, while the corresponding indexes of US bonds and British bonds have risen by 2% and fallen by 2% respectively. "Market expectations are still more hawkish than we expected," said Salman Ahmed, global head of macro and strategic asset allocation at Fidelity. "If downside risks become a reality, then the European Central Bank may cut interest rates further."Digital authentication has set up a new technology company in Tianjin. The enterprise search APP shows that Tianjin Mixin Tianxing Technology Co., Ltd. was recently established, with Cheng Xiaozhuo as the legal representative and a registered capital of 30 million yuan. Its business scope includes: electronic authentication services; Software development; Information system integration service; Network and information security software development, etc. Enterprise equity penetration shows that the company is wholly owned by Digital Certification.Bank of Communications International: For the first time, it covers the "buy" rating and target price of HK$ 5.86 given by the rich industrial trust. The Bank of Communications International published a report that the rich industrial trust has multiple investment advantages and stock price drivers, including stable profit prospects, low valuation, further interest rate cuts and potential inclusion in Shanghai-Shenzhen-Hong Kong Stock Connect, which are all beneficial to the valuation of REITs. For the first time, the bank covers the purchase of wealth and gives a "buy" rating with a target price of HK$ 5.86. Bank of Communications International believes that the rental income prospect of Zhifu Industrial Trust can remain basically stable. At the same time, the current share price corresponds to a dividend of 9.4% in 2025, and the gap between the dividend yield and the yield of 10-year US bonds is about 1.1 standard deviation lower than the long-term level. It is considered that the current valuation is still far below its long-term average level, and has reflected most of the worries of the retail market in Hong Kong. The report continued that although high interest rates will still have a negative impact on this year's earnings, it is expected that the dividend per unit of Zhifu will resume growth from next year under the condition of continuous interest rate reduction. It is expected that the dividend per unit will decrease by 10%, increase by 3.8% and increase by 4.1% from 2024 to 2026 to 36.34, 37.71 and 39.26 Hong Kong cents respectively.

Pacific Securities: Goldwind Technology's performance is expected to achieve rapid growth, with the first "buy" rating. Pacific Securities Research Report pointed out that with the profit recovery of wind turbine business and the contribution of wind farm investment and development and wind power service business, Goldwind Technology's (002202.SZ) performance is expected to achieve rapid growth. The first coverage gives a "buy" rating. Goldwind Technology has ranked first in the domestic wind power market for 13 consecutive years since 2011; However, in recent years, under the strong competitive pressure of wind turbine enterprises after the second line, their market share has declined. In the future, with the increase of market concentration, Goldwind Technology, as a leader, is expected to increase its share. At the end of the third quarter of 2024, the company's external order volume was 41.38GW, and sufficient in-hand order volume supported its share increase.The Jiading District Government of Shanghai organized statistics on the arrears of dealers. The reporter was informed that the relevant departments of the Jiading District Government of Shanghai have stepped in to count the arrears of dealers. At about 13: 00 on December 13th, the reporter of Beijing News Shell Finance saw at the registration site of Shanghai Yongqiao Village Committee that a staff member was organizing the dealers present to fill out the form, and the information collected included the name of the company, contact person, goods supplied, amount owed, due date, etc. (Shell Finance)The closing price of the national carbon market rose by 0.84% compared with the previous day. Today, the comprehensive price of the national carbon market is: the opening price is 99.66 yuan/ton, the highest price is 101.74 yuan/ton, the lowest price is 98.95 yuan/ton, and the closing price is 100.74 yuan/ton, which is 0.84% higher than the previous day. The transaction volume of today's listing agreement is 464,194 tons, with a turnover of 46,118,764.87 yuan; The volume of bulk agreement transactions was 4,617,079 tons, with a turnover of 450,306,945.18 yuan. Today, the total turnover of the national carbon emission quota is 5081273 tons, with a total turnover of 496425710.05 yuan. From January 1 to December 13, 2024, the volume of carbon emission quota in the national carbon market was 169,736,665 tons, with a turnover of 162,864,7748.47 yuan. As of December 13, 2024, the cumulative turnover of carbon emission quotas in the national carbon market was 611,359,276 tons, with a cumulative turnover of 412,056,282,67.75 yuan. (National Carbon Trading)

Chinese researchers have developed a new type of implantable cranial nerve probe. The reporter learned from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences that Zhang Qiang, a researcher at the institute, and his collaborators have developed a new type of implantable hydrogel neural probe to realize long-term stable monitoring of cranial nerve signals, precise regulation of neural circuits, and preliminary exploration in the application of diagnosis and treatment of severe brain diseases. Related research results were recently published in the international academic journal Advanced Materials. (Xinhua News Agency)6 Lianban Yibin Paper: The company's current P/B ratio is quite different from that of the same industry. Yibin Paper announced the abnormal fluctuation of stock trading. Since December 6, 2024, the company's stock has been trading daily for six consecutive trading days, with a cumulative increase of 77.12%. According to the data released by CSI official website, the latest P/B ratio of papermaking and packaging owned by the company is 1.69 times, and the latest P/B ratio of the company is 9.28 times. The current P/B ratio of the company is quite different from that of the same industry. Investors are advised to pay attention to risks.Borui Medicine: Carboprost injection is planned to win the bid for the national centralized drug procurement. Borui Medicine announced that in the tenth batch of national centralized drug procurement in which Borui Pharmaceutical, a wholly-owned subsidiary, participated, carboprost tromethamine injection is planned to win the bid. This product is mainly used for 13-20 weeks pregnant abortion and postpartum hemorrhage. The specification is 1 ml: 250μ g, and the proposed bid price is 16.96 yuan/piece. In the first year, the agreed purchase base is 220,400 pieces, which are mainly supplied to Henan, Hubei, Guangxi, Shaanxi, Gansu, Ningxia and other provinces. If the contract is finally selected and signed, it will help the product to quickly open the domestic market and enhance the market share and brand influence of the company. The product obtained the drug registration certificate in March 2024, and has not yet generated sales revenue.